major histocompatibility complex, class I, Z (pseudogene)Genealiases: []
Q-omics provides the consensus-scored HLA-Z profile across patient tissues and cancer cell-line models. HLA-Z expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, HLA-Z is differentially expressed in 11, with the highest sampling consensus in BRCA. Additionally, HLA-Z RNA expression shows 13,004 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight CESC, BRCA, and DLBC as cancer lineages where HLA-Z shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HLA-Z — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HLA-Z survival associations across molecular data types. HLA-Z RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HLA-Z RNA expression–survival associations across cancer types. High HLA-Z expression shows unfavorable associations in CESC, BLCA, UVM, COAD, THCA and OV. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for HLA-Z RNA expression.
This table summarizes HLA-Z tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for HLA-Z. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HLA-Z shows higher tumor expression in BRCA, STAD, LUAD, KIRC, BLCA and ESCA. The BRCA box plot shows higher HLA-Z RNA expression in tumor versus normal tissue (log2 FC = +0.322, t-test p < 0.001).
This table shows molecular features associated with HLA-Z in patient tissues and cancer cell lines. In patient samples, HLA-Z shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
